First trimester ultrasound assessment for fetal aneuploidy

Clinical Obstetrics and Gynecology

Volumn 57, Issue 1, 2014, Pages 142-158

  Hyett, Jon ^a,b   Mogra, Ritu ^a,b   Sonek, Jiri ^c  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b University of Sydney   (Australia)

^c WRIGHT STATE UNIVERSITY   (United States)

Author keywords

Aneuploidy; Fetus; Trisomy 21; Ultrasound

Indexed keywords

ANEUPLOIDY; BIOLOGICAL MARKERS; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; DOWN SYNDROME; FEMALE; HEART RATE, FETAL; HUMANS; NASAL BONE; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; ULTRASONOGRAPHY, PRENATAL; UMBILICAL VEINS;

EID: 84894079428     PISSN: 00099201     EISSN: 15325520     Source Type: Journal    
DOI: 10.1097/GRF.0000000000000013     Document Type: Article

References (132)

1. Richards BW, Stewart A, Sylvester PE, et al. Cytogenetic survey of 225 patients diagnosed clinically as mongols. J Ment Defic Res. 1965;9: 245-259
2. An assessment of the hazards of amniocentesis. Report to the Medical Research Council by their Working Party on Amniocentesis. Br J Obstet Gynaecol. 1978;85 (suppl 2):1-41
3. Tabor A, Philip J, Madsen M, et al. Randomised controlled trial of genetic amniocentesis in 4606 low-risk women. Lancet. 1986;1:1287-1293
4. Youings S, Gregson N, Jacobs P. The efficacy of maternal age screening for Downs syndrome in Wessex. Prenat Diagn. 1991;11:419-425
5. Wellesley D, Boyle T, Barber J, et al. Retrospective audit of different antenatal screening policies for Downs syndrome in eight district general hospitals in one health region. BMJ. 2002;325:15
6. Benn P, Rodis J, Beazoglou T. Cost-effectiveness of estimating gestational age by ultrasonography in Down Syndrome screening. Obstet Gynaecol. 1999;94:29-33
7. Smith-Bindman R, Chu P, Goldberg JD. Second trimester prenatal ultrasound for the detection of pregnancies at increased risk of Down syndrome. Prenat Diagn. 2007;27:535-544
8. Szabo J, Gellen J, Szemere G. First-Trimester ultrasound screening for fetal aneuploidies in women over 35 and under 35 years of age. Ultrasound Obstet Gynecol. 1995;5:161-163
9. Nicolaides KH, Azar G, Snijders RJ, et al. Fetal nuchal oedema: Associated malformations and chromosomal defects. Fetal Diagn Ther. 1992;7: 123-131
10. Azar GB, Snijders RJ, Gosden C, et al. Fetal nuchal cystic hygromata: Associated malformations and chromosomal defects. Fetal Diagn Ther. 1991;6:46-57
11. Nicolaides KH, Azar G, Byrne D, et al. Fetal nuchal translucency: Ultrasound screening for chromosomal defects in first trimester of pregnancy. BMJ. 1992;304:867-869
12. Molina FS, Avgidou K, Kagan KO, et al. Cystic hygromas, nuchal edema, and nuchal translucency at 11-14 weeks of gestation. Obstet Gynecol. 2006;107:678-683
13. Pandya PP, Altman DG, Brizot ML, et al. Repeatability of measurement of fetal nuchal translucency thickness. Ultrasound Obstet Gynecol. 1995;5:334-337
14. Snijders RJ, Noble P, Sebire N, et al. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-Translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet. 1998;352:343-346
15. Spencer K, Bindra R, Nix AB, et al. Delta-NT or NTMoM:which is the most appropriate method for calculating accurate patient-specific risks for trisomy 21 in the first trimester?. Ultrasound Obstet Gynecol. 2003;22:142-148
16. Wright D, Kagan KO, Molina FS, et al. A mixture model of nuchal translucency thickness in screening for chromosomal defects. Ultrasound Obstet Gynecol. 2008;31:376-383
17. Kagan KO, Wright D, Etchegaray A, et al. Effect of deviation of nuchal translucency measurements on the performance of screening for trisomy 21. Ultrasound Obstet Gynecol. 2009;33: 657-664
18. Evans MI, Krantz DA, Hallahan TW, et al. Undermeasurement of nuchal translucencies: Implications for screening. Obstet Gynecol. 2010; 116:815-818
19. Pajkrt E, van Lith JM, Mol BW, et al. Screening for Downs syndrome by fetal nuchal translucency measurement in a general obstetric population. Ultrasound Obstet Gynecol. 1998;12: 163-169
20. Kornman LH, Morssink LP, Beekhuis JR, et al. Nuchal translucency cannot be used as a screening test for chromosomal abnormalities in the first trimester of pregnancy in a routine ultrasound practice. Prenat Diagn. 1996;16:797-805
21. Zoppi MA, Ibba RM, Floris M, et al. Fetal nuchal translucency screening in 12495 pregnancies in Sardinia. Ultrasound Obstet Gynecol. 2001;18:649-651
22. Gasiorek-Wiens A, Tercanli S, Kozlowski P, et al. German-Speaking Down Syndrome Screening Group. Screening for trisomy 21 by fetal nuchal translucency and maternal age: A multicenter project in Germany, Austria and Switzerland. Ultrasound Obstet Gynecol. 2001; 18:645-648
23. Crossley JA, Aitken DA, Cameron AD, et al. Combined ultrasound and biochemical screening for Downs Syndrome in the first trimester: A Scottish multicentre study. BJOG. 2002;109: 667-676
24. Jacques A, Halliday J, Francis I, et al. Follow up and evaluation of the Victorian first-Trimester combined screening programme for down syndrome and trisomy 18. BJOG. 2007;114: 812-818
25. Wald NJ, Rodeck C, Hackshaw AK, et al. SURUSS Research Group. First and second trimester antenatal screening for Downs syndrome: The results of the Serum, Urine and Ultrasound Screening Study (SURUSS). Health Technol Assess. 2003;7:1-77
26. Spencer K, Spencer CE, Power M, et al. Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one-stop clinic: A review of three years prospective experience. BJOG. 2003;110:281-286
27. Malone FD, Canick JA, Ball RH, et al. First- and second-Trimester evaluation of risk (FASTER) research consortium. First-Trimester or second-Trimester screening, or both, for Downs syndrome. N Engl JMed. 2005;353:2001-2011
28. Monni G, Zoppi MA, Ibba RM, et al. Nuchal translucency and nasal bone for trisomy 21 screening: Single center experience. Croat Med J. 2005;46:786-791
29. Avgidou K, Papageorghiou A, Bindra R, et al. Prospective first-Trimester screening for trisomy 21 in 30,564 pregnancies. Am J Obstet Gynecol. 2005;192:1761-1767
30. Saltvedt S, Almstroäm H, Kublickas M, et al. Screening for Down syndrome based on maternal age or fetal nuchal translucency: A randomized controlled trial in 39,572 pregnancies. Ultrasound Obstet Gynecol. 2005;25: 537-545
31. MacRae R, Ojutiku D, Duke-MacRae J, et al. Evaluating nuchal translucency scans performed for trisomy screening in a district general hospital between July 1998 and January 2004. J Obstet Gynaecol. 2008;28:683-687
32. Okun N, Summers AM, Hoffman B, et al. Prospective experience with integrated prenatal screening and first trimester combined screening for trisomy 21 in a large Canadian urban center. Prenat Diagn. 2008;28:987-992
33. Kagan KO, Etchegaray A, Zhou Y, et al. Prospective validation of first-Trimester combined screening for trisomy 21. Ultrasound Obstet Gynecol. 2009;34:14-18
34. Schaelike M, Kossakiewicz M, Kossakiewicz A, et al. Examination of a first-Trimester Down syndrome screening concept on a mix of 11,107 high- and low-risk patients at a private center for prenatal medicine in Germany. Eur J Obstet Gynecol Reprod Biol. 2009;144:140-145
35. Sahota DS, Leung TY, Chan LW, et al. Comparison of first-Trimester contingent screening strategies for Down syndrome. Ultrasound Obstet Gynecol. 2010;35:286-291
36. Conner P, Westgren M, Marsk A, et al. Combined ultrasound and biochemistry for risk evaluation in the first trimester: The Stockholm experience of a new web-based system. Acta Obstet Gynecol Scand. 2012;91:34-38
37. Yeo GS, Lai FM, Wei X, et al. Validation of first trimester screening for trisomy 21 in Singapore with reference to performance of nasal bone. Fetal Diagn Ther. 2012;32:166-170
38. Ghaffari SR, Tahmasebpour AR, Jamal A, et al. First-Trimester screening for chromosomal abnormalities by integrated application of nuchal translucency, nasal bone, tricuspid regurgitation and ductus venosus flow combined with maternal serum free b-hCG and PAPP-A: A 5-year prospective study. Ultrasound Obstet Gynecol. 2012;39:528-534
39. Peuhkurinen S, Laitinen P, Honkasalo T, et al. Comparison of combined, biochemical and nuchal translucency screening for Down syndrome in first trimester in Northern Finland. Acta Obstet Gynecol Scand. 2013;92:769-774
40. Berktold L, von Kaisenberg CS, Hillemanns P, et al. Analysis of the impact of PAPP-A, free b-hCG and nuchal translucency thickness on the advanced first trimester screening. Arch Gynecol Obstet. 2013;287:413-420
41. Nicolaides KH. Nuchal translucency and other first-Trimester sonographic markers of chromosomal abnormalities.AmJ Obstet Gynecol. 2004; 191:45-67
42. Monni G, Zoppi MA, Ibba RM, et al. Fetal nuchal translucency test for Downs syndrome. Lancet. 1997;350:1631
43. Snijders RJ, Thom EA, Zachary JM, et al. Firsttrimester trisomy screening: Nuchal translucency measurement training and quality assurance to correct and unify technique. Ultrasound Obstet Gynecol. 2002;19:353-359
44. DAlton ME, Cleary-Goldman J, Lambert-Messerlian G, et al. Maintaining quality assurance for sonographic nuchal translucency measurement: Lessons from the FASTER Trial. Ultrasound Obstet Gynecol. 2009;33:142-146
45. Sahota DS, Leung WC, To WK, et al. Quality assurance of nuchal translucency for prenatal fetal Down syndrome screening. J Matern Fetal Neonatal Med. 2012;25:1039-1043
46. Evans MI, Krantz DA, Hallahan TW, et al. Impact of nuchal translucency credentialing by the FMF, the NTQR or both on screening distributions and performance. Ultrasound Obstet Gynecol. 2012;39:181-184
47. Nisbet DL, Robertson AC, Schluter PJ, et al. Auditing ultrasound assessment of fetal nuchal translucency thickness: A review of Australian National Data 2002-2008. Aust N Z J Obstet Gynaecol. 2010;50:450-455
48. Chalouhi GE, Salomon LJ, Fontanges M, et al. Formative assessment based on an audit and feedback improves nuchal translucency ultrasound image quality. J Ultrasound Med. 2013;32: 1601-1605
49. Hyett JA, Moscoso G, Nicolaides KH. Firsttrimester nuchal translucency and cardiac septal defects in fetuses with trisomy 21. Am J Obstet Gynecol. 1995;172:1411-1413
50. Hyett J, Moscoso G, Nicolaides K. Abnormalities of the heart and great arteries in first trimester chromosomally abnormal fetuses. Am J Med Genet. 1997;69:207-216
51. Hyett J, Moscoso G, Papapanagiotou G, et al. Abnormalities of the heart and great arteries in chromosomally normal fetuses with increased nuchal translucency thickness at 11-13 weeks of gestation. Ultrasound Obstet Gynecol. 1996;7: 245-250
52. Hyett J, Perdu M, Sharland G, et al. Using fetal nuchal translucency to screen for major congenital cardiac defects at 10-14 weeks of gestation: Population based cohort study. BMJ. 1999;318: 81-85
53. Hyett JA, Brizot ML, Von Kaisenberg CS, et al. Cardiac gene expression of atrial natriuretic peptide and brain natriuretic peptide in trisomic fetuses. Obstet Gynecol. 1996;87:506-510
54. Sotiriadis A, Papatheodorou S, Eleftheriades M, et al. Nuchal translucency and major congenital heart defects in fetuses with normal karyotype: A meta-Analysis. Ultrasound Obstet Gynecol. 2013; 42:383-389
55. Kagan KO, Wright D, Maiz N, et al. Screening for trisomy 18 by maternal age, fetal nuchal translucency, free B-human chorionic gonadotrophin and pregnancy-Associated plasma protein-A. Ultrasound Obstet Gynecol. 2008;32: 488-492
56. Ekelund CK, Petersen OB, Skibsted L, et al. Danish Fetal Medicine Research Group. Firsttrimester screening for trisomy 21 in Denmark: Implications for detection and birth rates of trisomy 18 and trisomy 13. Ultrasound Obstet Gynecol. 2011;38:140-144
57. Evans MI, Van Decruyes H, Nicolaides KH. Nuchal translucency measurements for first-Trimester screening: The price of inaccuracy. Fetal Diagn Ther. 2007;22:401-404
58. Down JLH. Observations on an ethnic classification of idiots. Clinical Lecture Reports, London Hospital. 1866;3:259-262
59. Sonek JD, Nicolaides KH. Prenatal ultrasonographic diagnosis of nasal bone abnormalities in three fetuses with Down syndrome. Am J Obstet Gynecol. 2002;186:139-141
60. Mogra R, Schluter PJ, Ogle RF, et al. A prospective cross-sectional study to define racial variation in fetal nasal bone length through ultrasound assessment at 18-20 weeks gestation. Aust N Z J Obstet Gynaecol. 2010;50:528-533
61. Cicero S, Curicio P, Papageorghiou A, et al. Absence of nasal bone in fetuses with trisomy 21 at 11-14 weeks of gestation: An observational study. Lancet. 2001;358:1665-1667
62. McLennan A, Schluter PJ, Pincham V, et al. First-Trimester fetal nasal bone audit: Evaluation of a novel method of image assessment. Ultrasound Obstet Gynecol. 2009;34:623-628
63. Cicero S, Bindra R, Rembouskos G, et al. Fetal nasal bone length in chromosomally normal and abnormal fetuses at 11-14 weeks of gestation. J Matern Fetal Neonatal Med. 2006;11:400-402
64. Orlandi F, Bilardo CM, Campogrande M, et al. Measurement of nasal bone length at 11-14 weeks of pregnancy and its potential role in down syndrome risk assessment. Ultrasound Obstet Gynecol. 2003;22:36-39
65. Viora E, Masturzo B, Errante G, et al. Ultrasound evaluation of fetal nasal bone at 11 to 14 weeks in a consecutive series of 1906 fetuses. Prenat Diagn. 2003;23:784-787
66. ZoppiMA, IbbaRM, Axiana C, et al. Absence of fetal nasal bone and aneuploidies at first-Trimester nuchal translucency screening in unselected pregnancies. Prenat Diagn. 2003;23:496-500
67. Malone FD, Ball RH, Nyberg DA, et al. Firsttrimester nasal bone evaluation for aneuploidy in the general population. Obstet Gynecol. 2004;104:1222-1228
68. Orlandi F, Rossi C, Orlandi E, et al. Firsttrimester screening for trisomy-21 using a simplified method to assess the presence or absence of the fetal nasal bone. Am J Obstet Gynecol. 2005;192:1107-1111
69. Cicero S, Avgidou K, Rembouskos G, et al. Nasal bone in first-Trimester screening for trisomy 21.AmJ Obstet Gynecol. 2006;195:109-114
70. Prefumo F, Sairam S, Bhide A, et al. Firsttrimester nuchal translucency, nasal bones, and trisomy 21 in selected and unselected populations. Am J Obstet Gynecol. 2006;194:828-833
71. Ramos-CorpasD, Santiago JC,Montoya F. Ultrasonographic evaluation of fetal nasal bone in a lowrisk population at 11-13+6 gestational weeks. Prenat Diagn. 2006;26:112-117
72. Sepulveda W, Wong AE, Dezerega V. First-Trimester ultrasonographic screening for trisomy 21 using fetal nuchal translucency and nasal bone. Obstet Gynecol. 2007;109:1040-1045
73. Moon MH, Cho JY, Lee YM, et al. First-Trimester screening for down syndrome; the role of nasal bone assessment in the Korean population. Prenat Diagn. 2007;27:830-834
74. Has R, Kalelioglu I, Yuksel A, et al. Fetal nasal bone assessment in first trimesterDown syndrome screening. Fetal Diagn Ther. 2008;24:61-66
75. Leung TY, Sahota D, Chan LW, et al. Fetal nasal bone status in Chinese women undergoing first-Trimester screening for trisomy 21. Am J Obstet Gynecol. 2008;199:521; e1-5
76. Kagan KO, Cicero S, Staboulidou I, et al. Fetal nasal bone in screening for trisomies 21, 18 and 13 and Turner syndrome at 11-13 weeks of gestation. Ultrasound Obstet Gynecol. 2009;33:259-264
77. Cicero S, Rembouskos G, Vandecruys H, et al. Likelihood ratio for trisomy 21 in fetuses with absent nasal bone at the 11-14-week scan. Ultrasound Obstet Gynecol. 2004;23:218-223
78. Karadzov-Orlic N, Egic A, Milovanovic Z, et al. Improved diagnostic accuracy by using secondary ultrasound markers in the first-Trimester screening for trisomies 21, 18 and 13 and Turner syndrome. Prenat Diagn. 2012;32:638-643
79. Cicero S, Dezerega V, Andrade E, et al. Learning curve for sonographic examination of the fetal nasal bone at 11-14 weeks. Ultrasound Obstet Gynecol. 2003;22:135-137
80. Woch A, Rozmus-Warcholinska W, Czuba B, et al. Doppler study of the embryonic heart in normal pregnant women. J Matern Fetal Neonatal Med. 2007;20:533-539
81. Hyett JA, Noble PL, Snijders RJ, et al. Fetal heart rate in trisomy 21 and other chromosomal abnormalities at 10-14 weeks of gestation. Ultrasound Obstet Gynecol. 1996;7:239-244
82. Kagan KO, Wright D, Valencia C, et al. Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free beta-hCG and pregnancy-Associated plasma protein-A. Hum Reprod. 2008;23: 1968-1975
83. Matias A, Gomes C, Flack N, et al. Screening for chromosomal abnormalities at 10-14 weeks: The role of ductus venosus blood flow. Ultrasound Obstet Gynecol. 1998;12:380-384
84. Borrell A, Antolin E, Costa D, et al. Abnormal ductus venosus blood flow in trisomy 21 fetuses during early pregnancy. Am J Obstet Gynecol. 1998;179:1612-1617
85. Maiz N, Valencia C, Kagan KO, et al. Ductus venosus Doppler in screening for trisomies 21, 18 and 13 and Turner syndrome at 11-13 weeks of gestation. Ultrasound Obstet Gynecol. 2009;33: 512-517
86. Toyama JM, Brizot ML, Liao AW, et al. Ductus venosus blood flow assessment at 11 to 14 weeks of gestation and fetal outcome. Ultrasound Obstet Gynecol. 2004;23:341-345
87. Borrell A, Gonce A, Martinez JM, et al. Firsttrimester screening for Down syndrome with ductus venosus Doppler studies in addition to nuchal translucency and serum markers. Prenat Diagn. 2005;25:901-905
88. Geipel A, Willruth A, Vieten J, et al. Nuchal fold thickness, nasal bone absence or hypoplasia, ductus venosus reversed flow and tricuspid valve regurgitation in screening for trisomies 21, 18 and 13 in the early second trimester. Ultrasound Obstet Gynecol. 2010;35:535-539
89. Sainz JA, Serrano R, Borrero C, et al. First trimester contingent test as a screening method for Downs syndrome.Aprospective study in the general population. J Matern Fetal Neonatal Med. 2012;25:2221-2224
90. Illa M, Mula R, Arigita M, et al. Likelihood ratios to apply for nasal bone, ductus venosus and tricuspid flow at the 11-13 weeks scan in down syndrome screening. Fetal Diagn Ther. 2013;34:116-120
91. Kagan KO, Staboulidou I, Cruz J, et al. Twostage first-Trimester screening for trisomy 21 by ultrasound assessment and biochemical testing. Ultrasound Obstet Gynecol. 2010;36:542-547
92. Sabria J, Comas C, Barceloá-Vidal C, et al. Updated reference ranges for the ductus venosus pulsatility index at 11-13 weeks. Fetal Diagn Ther. 2012;32:271-276
93. Wald NJ, Bestwick JP, Borrell A. Adding ductus venosus blood flow as a categorical variable to the Combined and Integrated tests in Downs syndrome screening. J Med Screen. 2012;19: 49-50
94. Maiz N, Wright D, Ferreira AF, et al. A mixture model of ductus venosus pulsatility index in screening for aneuploidies at 11-13 weeks gestation. Fetal Diagn Ther. 2012;31:221-229
95. Sonek J, Borenstein M, Dagklis T, et al. Frontomaxillary facial angle in fetuses with trisomy 21 at 11-13(6) weeks. Am J Obstet Gynecol. 2007; 196:271; e1-4
96. Borenstein M, Persico N, Kagan KO, et al. Frontomaxillary facial angle in screening for trisomy 21 at 11+0 to 13+6 weeks. Ultrasound Obstet Gynecol. 2008;35:5-11
97. Huggon IC, DeFigueiredo DB, Allan LD. Tricuspid regurgitation in the diagnosis of chromosomal anomalies in the fetus at 11-14 weeks gestation. Heart. 2003;89:1071-1073
98. Faiola S, Tsoi E, Huggon IC, et al. Likelihood ratio for trisomy 21 in fetuses with regurgitation at the 11 to 13+6 week scan. Ultrasound Obstet Gynecol. 2005;26:22-27
99. Falcon O, Faiola S, Huggon I, et al. Fetal tricuspid regurgitation at the 11+0 to 13+6 week scan association with chromosomal defects and reproducibility of the method. Ultrasound Obstet Gynaecol. 2006;27:609-612
100. Falcon O, Auer M, Gerovassili A, et al. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free B hCG and PaPP-A at 11+0 to 13+6 weeks. Ultrasound Obstet Gynaecol. 2006; 27:151-155
101. Nicolaides KH, Spencer K, Avgidou K, et al. Multicentre study of first-Trimester screening for trisomy 21 in 75821 pregnancies: Results and estimation of the potential impact of individual riskorientated two stage first trimester screening. Ultrasound Obstet Gynaecol. 2005;25:221-226
102. Kagan KO, Valencia C, Livanos P, et al. Tricuspid regurgitation in screening for trisomies 21, 18 and 13 and Turner syndrome at 11+0 to 13+6 weeks of gestation. Ultrasound Obstet Gynecol. 2009;33:18-22
103. Berg JM, Crome L, France NE. Congenital cardiac malformations in mongolism. Br Heart J. 1960;22:331-346
104. Rathore MH, Sreenivasan VV. Vertebral and right subclavian artery abnormalities in the Down syndrome. Am J Cardiol. 1989;63: 1528-1529
105. Chaoui R, Heling KS, Sarioglu N, et al. Aberrant right subclavian artery as a new cardiac sign in second- and third-Trimester fetuses with Down syndrome.AmJObstetGynecol. 2005;192:257-263
106. Zalel Y, Achiron R, Yagel S, et al. Fetal aberrant right subclavian artery in normal and Down syndrome fetuses. Ultrasound Obstet Gynecol. 2008;31:25-29
107. Yazicioglu HF, Sevket O, Akin H, et al. Aberrant right subclavian artery in Down syndrome fetuses. Prenat Diagn. 2013;33:209-213
108. Borenstein M, Cavoretto P, Allan L, et al. Aberrant right subclavian artery at 11+0 to 13+6weeks of gestation in chromosomally normal and abnormal fetuses. Ultrasound Obstet Gynecol. 2008;31:20-24
109. Zapata H, Edwards JE, Titus JL. Aberrant right subclavian artery with left aortic arch: Associated cardiac anomalies. Pediatr Cardiol. 1993;14: 159-161
110. Dagklis T, Plasencia W, Maiz N, et al. Choroid plexus cyst, intracardiac echogenic focus, hyperechogenic bowel and hydronephrosis in screening for trisomy 21 at 11+0 to 13+6 weeks. Ultrasound Obstet Gynecol. 2008;31:132-135
111. Sepulveda W, Dezerega V, Be C. First-Trimester sonographic diagnosis of holoprosencephaly: Value of the "butterfly" sign. J Ultrasound Med. 2004;23:761-765
112. Seller MJ. Neural tube defects, chromosome abnormalities and multiple closure sites for the human neural tube. Clin Dysmorphol. 1995;4: 202-207
113. Khalil A, Arnaoutoglou C, Pacilli M, et al. Outcome of fetal exomphalos diagnosed at 11-14 weeks of gestation. Ultrasound Obstet Gynecol. 2012;39:401-406
114. Liao AW, Sebire NJ, Geerts L, et al. Megacystis at 10-14 weeks of gestation: Chromosomal defects and outcome according to bladder length. Ultrasound Obstet Gynecol. 2003;21:338-341
115. Kagan KO, Staboulidou I, Syngelaki A, et al. The 11-13-week scan: Diagnosis and outcome of holoprosencephaly, exomphalos and megacystis. Ultrasound Obstet Gynecol. 2010;36: 10-14
116. ACOGCommittee on Practice Bulletins.ACOG Practice Bulletin No. 77: Screening for fetal chromosomal abnormalities. Obstet Gynecol. 2007;109:217-227
117. Syngelaki A, Chelemen T, Dagklis T, et al. Challenges in the diagnosis of fetal non-chromosomal abnormalities at 11-13 weeks. Prenat Diagn. 2011;31:90-102
118. Rossi AC, Prefumo F. Accuracy of ultrasonography at 11-14 weeks of gestation for detection of fetal structural anomalies: A systematic review. Obstet Gynecol. 2013. [Epub ahead of print
119. Bennett KA, Crane JM, Oshea P, et al. First trimester ultrasound screening is effective in reducing postterm labor induction rates: A randomized controlled trial. Am J Obstet Gynecol. 2004;190:1077-1081
120. Sebire NJ, Snijders RJ, Hughes K, et al. The hiddenmortality ofmonochorionic twin pregnancies. Br J Obstet Gynaecol. 1997;104:1203-1207
121. Ghalili A, McLennan A, Pedersen L, et al. Outcomes ofmonochorionic diamniotic twin pregnancies: A comparison of assisted and spontaneous conceptions. Aust N Z J Obstet Gynaecol. 2013;53: 437-442
122. Poon LC, Kametas NA, Maiz N, et al. Firsttrimester prediction of hypertensive disorders in pregnancy. Hypertension. 2009;53:812-818
123. Poon LC, Syngelaki A, Akolekar R, et al. Combined screening for preeclampsia and small for gestational age at 11-13 weeks. Fetal Diagn Ther. 2013;33:16-27
124. Greco E, Gupta R, Syngelaki A, et al. Firsttrimester screening for spontaneous preterm delivery with maternal characteristics and cervical length. Fetal Diagn Ther. 2012;31:154-161
125. Park FJ, Leung CH, Poon LC, et al. Clinical evaluation of a first trimester algorithm predicting the risk of hypertensive disease of pregnancy. Aust N Z J Obstet Gynaecol. 2013;53: 532-559
126. Roberge S, Nicolaides KH, Demers S, et al. Prevention of perinatal death and adverse perinatal outcome using low-dose aspirin: A metaanalysis. Ultrasound Obstet Gynecol. 2013;41: 491-499
127. ACOG Practice Guideline. Noninvasive prenatal testing for fetal aneuploidy. Committee Opinion No. 545. American College of Obstetricians and Gynecologists. Obstet Gynecol. 2012; 120:1532-1534
128. Alamillo CM, Krantz D, Evans M, et al. Nearly a third of abnormalities found after first-Trimester screening are different than expected: 10-year experience from a single center. Prenat Diagn. 2013;33:251-256
129. Gil MM, Quezada MS, Bregant B, et al. Implementation of maternal blood cell-free DNA testing in early screening for aneuploidies. Ultrasound Obstet Gynecol. 2013;42:34-40
130. Nicolaides KH, Syngelaki A, Poon LC, et al. First-Trimester contingent screening for trisomies 21, 18 and 13 by biomarkers and maternal blood cell-free DNA testing. Fetal Diagn Ther. 2013. [Epub ahead of print
131. Hui L, Hyett J. Noninvasive prenatal testing for trisomy 21: Challenges for implementation in Australia. Aust N Z J Obstet Gynaecol. 2013;53: 416-424
132. Nicolaides KH. A model for a new pyramid of prenatal care based on the 11 to 13 weeks assessment. Prenat Diagn. 2011;31:3-6